<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096547</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 2019-06-078</org_study_id>
    <nct_id>NCT04096547</nct_id>
  </id_info>
  <brief_title>Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment</brief_title>
  <acronym>XAIENT</acronym>
  <official_title>A Prospective, Non-interventional, Multicenter Observational Study to Evaluate the Effectiveness and Safety of Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Type and Design Prospective, Observational Study Rivaroxaban in Elderly AF patients&#xD;
      with or without renal impairment in Korea&#xD;
&#xD;
      This study will investigate effectiveness and safety in elderly patients, the result from&#xD;
      well-designed and high-quality prospective clinical registry collected through real-world&#xD;
      clinical practice is expected to resolve current medical unmet needs of rivaroxaban in Korean&#xD;
      elderly patients.&#xD;
&#xD;
      Primary Study Objective(s) To investigate the effectiveness of rivaroxaban in elderly&#xD;
      patients with NVAF, with or without renal impairment in Korea real-world clinical practice&#xD;
      settings Secondary Study Objective(s) To see safety outcome including major bleeding,&#xD;
      clinically non-major bleeding, all-cause mortality rivaroxaban in subgroup based on risk&#xD;
      factor(eg. Renal impairment) physicians' treatment pattern in rivaroxaban&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Population Elderly patients with age ≥ 65 years with treatment naïve or&#xD;
      treatment-experienced patients who are diagnosed with NVAF Expected number of patient&#xD;
      enrollment is about 1200 patients, Samsung Medical Center is aim to enroll about 200 patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite incidence of stroke/ non-CNS SE</measure>
    <time_frame>1 year</time_frame>
    <description>incidence of stroke/ non-CNS SE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding incidence</measure>
    <time_frame>1 year</time_frame>
    <description>Bleeding incidence</description>
  </secondary_outcome>
  <other_outcome>
    <measure>renal function</measure>
    <time_frame>1 year</time_frame>
    <description>CCl</description>
  </other_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Rivaroxaban</condition>
  <condition>Elderly</condition>
  <condition>Renal Insufficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>rivaroxaban for stroke prevention of atrial fibrillation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly patients with age ≥ 65 years with treatment naïve or treatment-experienced patients&#xD;
        who are diagnosed with NVAF Expected number of patient enrollment is about 1200 patients,&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with consent given&#xD;
&#xD;
          2. Elderly patients with age 65 ≥ years old&#xD;
&#xD;
          3. NVAF patients first time prescription to rivaroxaban or patients who started&#xD;
             rivaroxaban treatment within 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal to participate in this study or to give an informed consent&#xD;
&#xD;
          2. Patients with moderate to severe mitral stenosis&#xD;
&#xD;
          3. Patients with mechanical valve&#xD;
&#xD;
          4. Contraindication from rivaroxaban Korea SmPC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Keun On, MD</last_name>
      <phone>82-2-3410-3420</phone>
      <email>yk.on@samsung.com</email>
    </contact>
    <contact_backup>
      <last_name>MInteresa Ryu, RN</last_name>
      <email>minteresa816@naver.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Young Keun On</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

